Deal Closes Smoothly

The most likely outcome is that Merck KGaA completes the agreed cash acquisition of Silence Therapeutics, with limited regulatory resistance because the parties have little direct product overlap. The deal gives Merck KGaA a stronger RNAi platform after Silence's positive blood-cancer data and broader investor interest in genetic medicines.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.